Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV ...

Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical ...

Herpes simplex virus is a master of bad timing—reappearing briefly, often unnoticed, and just long enough to keep the immune system on its toes. In its genital form, herpes simplex virus type 2 (HSV-2 ...

Dr. Prince will provide an overview of Herpes Simplex Virus (HSV), including the distinctions between HSV-1 and HSV-2, their anatomical sites of infection, and the mechanisms underlying viral ...

The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase ...

Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020. (HealthDay News) — The incidence and prevalence of genital ...

Even though genital herpes is fairly common (roughly one in six Americans has it, according to the Centers for Disease Control & Prevention [CDC]), it's highly stigmatized, in large part because ...

Infection with HSV can cause oral or genital warts, but it can also be fully asymptomatic. There are two types of HSV: herpes type 1 (HSV-1), mainly spread through oral contact herpes type 2 (HSV-2), ...